

Pierre Gantner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4303605/publications.pdf>

Version: 2024-02-01

26
papers

501
citations

758635

12
h-index

713013

21
g-index

27
all docs

27
docs citations

27
times ranked

1002
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART. <i>Nature Communications</i> , 2020, 11, 4089.	5.8	77
2	A new hot spot for tick-borne encephalitis (TBE): A marked increase of TBE cases in France in 2016. <i>Ticks and Tick-borne Diseases</i> , 2018, 9, 120-125.	1.1	49
3	The multifaceted nature of HIV latency. <i>Journal of Clinical Investigation</i> , 2020, 130, 3381-3390.	3.9	49
4	Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. <i>HIV Medicine</i> , 2017, 18, 704-708.	1.0	45
5	In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia. <i>Nature Communications</i> , 2021, 12, 3727.	5.8	43
6	Torquetenovirus viremia for early prediction of graft rejection after kidney transplantation. <i>Journal of Infection</i> , 2019, 79, 56-60.	1.7	40
7	Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	20
8	Tick-borne encephalitis virus: molecular determinants of neuropathogenesis of an emerging pathogen. <i>Critical Reviews in Microbiology</i> , 2019, 45, 472-493.	2.7	19
9	Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 751-761.	1.3	18
10	HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3202-3205.	1.3	17
11	Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection. <i>PLoS ONE</i> , 2019, 14, e0215464.	1.1	17
12	Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1 infected patients: a cohort study. <i>HIV Medicine</i> , 2015, 16, 132-136.	1.0	15
13	Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies. <i>Journal of Medical Virology</i> , 2017, 89, 2047-2050.	2.5	10
14	Predictors of Standard Follow-Up Completion after Sexual Exposure to HIV: Five-Year Retrospective Analysis in a French HIV-Infection Care Center. <i>PLoS ONE</i> , 2015, 10, e0145440.	1.1	10
15	Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 838-845.	1.5	9
16	Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1045-1053.	1.3	9
17	Genital reservoir. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 395-401.	1.5	8
18	Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 183-193.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1537-1539.	2.8	8
20	Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice. <i>PLoS ONE</i> , 2016, 11, e0164240.	1.1	5
21	Problem-based learning in laboratory medicine resident education: a satisfaction survey. <i>Annales De Biologie Clinique</i> , 2017, 75, 181-192.	0.2	5
22	Distribution and reduction magnitude of HIV-DNA burden in CD4+ T cell subsets depend on art initiation timing. <i>Aids</i> , 2018, 32, 921-926.	1.0	4
23	Elvitegravirâ€“Cobicistatâ€“Emtricitabineâ€“Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2019, 70, 943-946.	2.9	4
24	â€œReal lifeâ€•use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study. <i>PLoS ONE</i> , 2019, 14, e0216010.	1.1	3
25	Postâ€•exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV*. <i>HIV Medicine</i> , 2020, 21, 463-469.	1.0	1
26	Performance of the LiaisonÂ® XL Murex recHTLV-I/II Immunoassay in the Detection of HTLV-1/2 Antibodies in Serum. <i>Clinical Laboratory</i> , 2017, 63, 997-1001.	0.2	1